Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jan;29(1):115-117.
doi: 10.1016/j.jiac.2022.09.019. Epub 2022 Sep 30.

Diagnostic test property of transcription-reverse transcription concerted reaction reagent TRCReady® SARS-CoV-2 i using nasopharyngeal swab samples

Megumi Ogawa  1 , Manami Sato  1 , Asuka Yamakami  1 , Yuki Hayasaka  1 , Yoshiko Saya  1 , Kurando Une  2 , Satoshi Iwai  2 , Shigeo Tsuchiya  2 , Yumiko Mikami  1 , Chizumi Fukazawa  1 , Yuki Uehara  3
Affiliations

Diagnostic test property of transcription-reverse transcription concerted reaction reagent TRCReady® SARS-CoV-2 i using nasopharyngeal swab samples

Megumi Ogawa et al. J Infect Chemother. 2023 Jan.

Abstract

TRCReady® SARS-CoV-2 i is a reagent for transcription-reverse transcription concerted reaction (TRC) to detect SARS-CoV-2 N2 gene, used with the automated rapid isothermal nucleic acid amplification test (NAAT) analyzer TRCReady®-80. Sensitivity and specificity of TRCReady® SARS-CoV-2 i was assessed by comparison with the results of real-time reverse transcription-polymerase chain reaction (RT-PCR) using nasopharyngeal swab samples. From November 2020 to March 2021, a total of 441 nasopharyngeal swabs were obtained and analyzed both with TRCReady® SARS-CoV-2 i and RT-PCR. Sensitivity and specificity of TRCReady® SARS-CoV-2 i were 94.6% (53/56) and 99.2% (382/385), respectively. Reaction time to positivity of TRCReady® SARS-CoV-2 i ranged from 1.166 to 9.805 (median: 2.887) min, and minimum detection sensitivity of TRCReady® SARS-CoV-2 i was 9 copies per test, with reaction time as 5.014 min. Detection of SARS-CoV-2 gene from nasopharyngeal swab sample using TRCReady® SARS-CoV-2 i shows comparative diagnostic test accuracy with RT-PCR, and can be used as a useful test to diagnose SARS-CoV-2 infection.

Keywords: Nasopharyngeal swab; Novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Rapid nucleic acid amplification test; TRCReady® SARS-CoV-2 i; Transcription-reverse transcription concerted reaction.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest KU, SI and ST are the employees of Tosoh Corporation. The reagent TRCReady® SARS-CoV-2 i and part of publication fee of this study was provided by Tosoh Corporation.

Figures

Fig. 1
Fig. 1
Correlation of the time to positivity of TRCReady® SARS-CoV-2 i and RT-PCR. RT-PCR, real-time reverse transcription-polymerase chain reaction.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ishiguro T., Saitoh J., Yawata H., Otsuka M., Inoue T., Sugiura Y. Fluorescence detection of specific sequence of nucleic acids by oxazole yellow-linked oligonucleotides. Homogeneous quantitative monitoring of in vitro transcription. Nucleic Acids Res. 1996;24:4992–4997. doi: 10.1093/nar/24.24.4992. - DOI - PMC - PubMed
    1. Drouillon V., Delogu G., Dettori G., Lagrange P.H., Benecchi M., Houriez F., et al. Multicenter evaluation of a transcription-reverse transcription concerted assay for rapid detection of mycobacterium tuberculosis complex in clinical specimens. J Clin Microbiol. 2009;47:3461–3465. doi: 10.1128/JCM.01730-08. - DOI - PMC - PubMed
    1. Takakura S., Tsuchiya S., Isawa Y., Yasukawa K., Hayashi T., Tomita M., et al. Rapid detection of Mycobacterium tuberculosis in respiratory samples by transcription-reverse transcription concerted reaction with an automated system. J Clin Microbiol. 2005;43:5435–5439. doi: 10.1128/JCM.43.11.5435-5439.2005. - DOI - PMC - PubMed
    1. Sato Y., Nirasawa S., Saeki M., Yakuwa Y., Ono M., Yanagihara N., et al. Evaluation of two commercial molecular diagnostic assays: the Xpert Norovirus and the TRCReady NV. J Infect Chemother. 2021;27:1115–1118. doi: 10.1016/j.jiac.2021.02.004. - DOI - PubMed
    1. Shikano H., Uehara Y., Kuboki R., Tashino E., Nakahara F., Matsumoto Y., et al. Retrospective evaluation of the symptom-based work restriction strategy of healthcare providers in the first epidemic of COVID-19 at a tertiary care hospital in Tokyo, Japan. Am J Infect Control. 2022;50(6):645–650. doi: 10.1016/j.ajic.2021.11.029. - DOI - PMC - PubMed

Substances